Country origin: Sweden
With early intervention, the MARS system may help improve or preserve multi-organ function by facilitating an improved environment for hepatic regeneration and clinical recovery.
With early intervention, MARS (Molecular Adsorbent Recirculating System) provides liver support and helps prevent the evolution of multiorgan failure contributing to an improved environment for hepatic regeneration and clinical recovery. MARS removes protein-bound and water-soluble toxins with albumin dialysis. This reduces plasma toxicity, improves patient clinical conditions (hemodynamics, hepatic encephalopathy, urine output), enhances the regeneration of liver cells and may help to recover native liver functions.
Clinically applied since 1993, the MARS system is the most extensively used non-biological liver support therapy in the world, with an ever-growing base of clinical experience and evidence covering more than 15,000 patients from 150 centers in more than 40 different countries. The MARS system is compatible with several standard hemodialysis machines and CRRT devices, and requires minimal staff involvement before and during treatment.
Gambro’s latest development the Prismaflex eXeed II software enables you to prescribe MARS through a dedicated CRRT system user interface. The Prismaflex user interface displays on-line instructions to guide you through Prismaflex MARS therapy setup and to simplify therapy implementation. This latest development makes the Prismaflex system the ideal device for implementing both CRRT and the MARS therapy.
The MARS® device is cleared for use in the U.S. in the treatment of drug overdose and poisonings as well as hepatic encephalopathy (HE) due to a decompensation of a chronic liver disease. It is not indicated in the U.S. as a bridge to liver transplant.